The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type ...

The FDA has received six adverse event reports connected to this specific lot of Ozempic (all submitted by Novo Nordisk), but ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

The Food and Drug Administration issued an alert on Monday concerning counterfeit Ozempic that could be in the U.S. drug ...

Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 ... negotiation for their key drug semaglutide, Wegovy/Ozempic/Rybelsus, in 2027 - it’s not clear how far the Trump ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand ... including GLP-1 medicines like Ozempic and Wegovy, Novo said in a Portuguese-language press ...

Novo Nordisk is considering launching its weight ... The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months ...

Novo Nordisk (NYSE:NVO)) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to supercharge its manufacturing plant in Montes Claros.